MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

MDT

96.1

-0.44%↓

A

137.81

-0.48%↓

VEEV

224.76

+0.38%↑

HQY

92.67

-0.47%↓

PHR.US

16.99

-0.18%↓

Search

TransMedics Group Inc

Fechado

SetorSaúde

122.89 -0.58

Visão Geral

Variação de preço das ações

24h

Atual

Mín

122

Máximo

124.92

Indicadores-chave

By Trading Economics

Rendimento

-11M

24M

Vendas

-14M

144M

P/E

Médio do Setor

50.331

78.892

Margem de lucro

16.909

Funcionários

728

EBITDA

-13M

33M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+19% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-95M

4.4B

Abertura anterior

123.47

Fecho anterior

122.89

Sentimento de Notícias

By Acuity

28%

72%

66 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bearish Evidence

TransMedics Group Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de ago. de 2025, 19:15 UTC

Grandes Movimentos do Mercado

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Comparação entre Pares

Variação de preço

TransMedics Group Inc Previsão

Preço-alvo

By TipRanks

19% parte superior

Previsão para 12 meses

Média 147.8 USD  19%

Máximo 170 USD

Mínimo 115 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para TransMedics Group Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

9

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

92.43 / 94.18Suporte e Resistência

Curto Prazo

Weak Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bullish Evidence

Sentimento

By Acuity

66 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat